Cancer

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment…

3 months ago

Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD

New U.S. patent provides IP coverage for the formulation to 2042Further expands Starton’s intellectual property portfolio surrounding its lead product…

3 months ago

Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD

New U.S. patent provides IP coverage for the formulation to 2042Further expands Starton’s intellectual property portfolio surrounding its lead product…

3 months ago

Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced…

3 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

First patient in South Korea dosedMIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the…

3 months ago

AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comPHOENIX and LONDON, Sept.…

3 months ago

Focal One® HIFU Receives Prestigious Innovation Award

          Focal One® HIFU Receives Prestigious Innovation Award AUSTIN, Texas, September 16, 2025 - EDAP TMS…

3 months ago

Defence Therapeutics Appoints Dr. Amie Phinney as Director

Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"),…

3 months ago

Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000

Montreal, Quebec--(Newsfile Corp. - September 15, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a…

3 months ago